Development and Validation of a Multi-institutional Nomogram of Outcomes for PSMA-PET–Based Salvage Radiotherapy for Recurrent Prostate Cancer
JAMA Network Open · 2023
DOI: 10.1001/jamanetworkopen.2023.14748 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift JAMA Network Open, 2023. Verfasst von Constantinos Zamboglou und 29 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany. Hauptthemen laut MEDLINE: Prostatic Neoplasms. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Prostate-specific antigen membrane positron-emission tomography (PSMA-PET) is increasingly used to guide salvage radiotherapy (sRT) after radical prostatectomy for patients with recurrent or persistent prostate cancer.
Objective
To develop and validate a nomogram for prediction of freedom from biochemical failure (FFBF) after PSMA-PET–based sRT. Design, Setting, and Participants This retrospective cohort study included 1029 patients with prostate cancer treated between July 1, 2013, and June 30, 2020, at 11 centers from 5 countries. The initial database consisted of 1221 patients. All patients had a PSMA-PET scan prior to sRT. Data were analyzed in November 2022. Exposures Patients with a detectable post–radical prostatectomy prostate-specific antigen (PSA) level treated with sRT to the prostatic fossa with or without additional sRT to pelvic lymphatics or concurrent androgen deprivation therapy (ADT) were eligible. Main Outcomes and Measures The FFBF rate was estimated, and a predictive nomogram was generated and validated. Biochemical relapse was defined as a PSA nadir of 0.2 ng/mL after sRT.
Results
In the nomogram creation and validation process, 1029 patients (median age at sRT, 70 years [IQR, 64-74 years]) were included and further divided into a training set (n = 708), internal validation set (n = 271), and external outlier validation set (n = 50). The median follow-up was 32 months (IQR, 21-45 months). Based on the PSMA-PET scan prior to sRT, 437 patients (42.5%) had local recurrences and 313 patients (30.4%) had nodal recurrences. Pelvic lymphatics were electively irradiated for 395 patients (38.4%). All patients received sRT to the prostatic fossa: 103 (10.0%) received a dose of less than 66 Gy, 551 (53.5%) received a dose of 66 to 70 Gy, and 375 (36.5%) received a dose of more than 70 Gy. Androgen deprivation therapy was given to 325 (31.6%) patients. On multivariable Cox proportional hazards regression analysis, pre-sRT PSA level (hazard ratio [HR], 1.80 [95% CI, 1.41-2.31]), International Society of Urological Pathology grade in surgery specimen (grade 5 vs 1+2: HR, 2.39 [95% CI, 1.63-3.50], pT stage (pT3b+pT4 vs pT2: HR, 1.91 [95% CI, 1.39-2.67]), surgical margins (R0 vs R1+R2+Rx: HR, 0.60 [95% CI, 0.48-0.78]), ADT use (HR, 0.49 [95% CI, 0.37-0.65]), sRT dose (>70 vs ≤66 Gy: HR, 0.44 [95% CI, 0.29-0.67]), and nodal recurrence detected on PSMA-PET scans (HR, 1.42 [95% CI, 1.09-1.85]) were associated with FFBF. The mean (SD) nomogram concordance index for FFBF was 0.72 (0.06) for the internal validation cohort and 0.67 (0.11) in the external outlier validation cohort. Conclusions and Relevance This cohort study of patients with prostate cancer presents an internally and externally validated nomogram that estimated individual patient outcomes after PSMA-PET–guided sRT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
- German Cancer Consortium (DKTK), Partner Site Freiburg, Freiburg, Germany.
- Berta-Ottenstein-Programme, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
- German Oncology Center, University Hospital of the European University, Limassol, Cyprus.
- Department of Radiation Oncology, Klinikum rechts der Isar, Technical University of Munich (TUM), Munich, Germany.
- Institute of Radiation Medicine (IRM), Department of Radiation Sciences (DRS), Helmholtz Zentrum, München, Germany.
Zitieren
APA
Zamboglou, C., Peeken, J. C., Janbain, A., Katsahian, S., Strouthos, I., Ferentinos, K., Farolfi, A., Koerber, S. A., Debus, J., Vogel, M. E., Combs, S. E., Vrachimis, A., Morganti, A. G., Spohn, S. K. B., Shelan, M., Aebersold, D. M., Grosu, A. L., Ceci, F., Henkenberens, C., …, & Schmidt-Hegemann, N. S. (2023). Development and Validation of a Multi-institutional Nomogram of Outcomes for PSMA-PET–Based Salvage Radiotherapy for Recurrent Prostate Cancer. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2023.14748
Vancouver
Zamboglou C, Peeken JC, Janbain A, Katsahian S, Strouthos I, Ferentinos K, et al. Development and Validation of a Multi-institutional Nomogram of Outcomes for PSMA-PET–Based Salvage Radiotherapy for Recurrent Prostate Cancer. JAMA Network Open. 2023. doi:10.1001/jamanetworkopen.2023.14748
BibTeX
@article{Zamboglou2023,
author = {Zamboglou, Constantinos and Peeken, Jan C and Janbain, Ali and Katsahian, Sandrine and Strouthos, Iosif and Ferentinos, Konstantinos and Farolfi, Andrea and Koerber, Stefan A and Debus, Juergen and Vogel, Marco E and Combs, Stephanie E and Vrachimis, Alexis and Morganti, Alessio Giuseppe and Spohn, Simon K B and Shelan, Mohamed and Aebersold, Daniel M and Grosu, Anca-Ligia and Ceci, Francesco and Henkenberens, Christoph and Kroeze, Stephanie G C and Guckenberger, Matthias and Fanti, Stefano and Belka, Claus and Bartenstein, Peter and Hruby, George and Scharl, Sophia and Wiegel, Thomas and Emmett, Louise and Arnoux, Armelle and Schmidt-Hegemann, Nina-Sophie},
title = {Development and Validation of a Multi-institutional Nomogram of Outcomes for PSMA-PET–Based Salvage Radiotherapy for Recurrent Prostate Cancer},
journal = {JAMA Network Open},
year = {2023},
doi = {10.1001/jamanetworkopen.2023.14748}
}
EUVIMED